Reprogrammed Interchange Llc Sells 7,901 Shares of Vor Biopharma (NYSE:VOR) Stock

Vor Biopharma Inc. (NYSE:VOR) major shareholder Reprogrammed Interchange Llc sold 7,901 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83. Following the completion of the sale, the insider owned 1,597,308 shares in the company, valued at approximately $60,426,161.64. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The stock was sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $37.46 on Friday. The stock has a market cap of $256.75 million, a price-to-earnings ratio of -22.70 and a beta of 2.07. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The firm has a 50-day moving average of $38.88 and a two-hundred day moving average of $24.20.

Institutional Trading of Vor Biopharma

Institutional investors have recently modified their holdings of the stock. Money Concepts Capital Corp grew its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the second quarter valued at about $66,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma in the first quarter valued at about $100,000. Finally, Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the first quarter valued at about $140,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

VOR has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Finally, Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Wednesday, September 24th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $113.83.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.